AT282418T - Oral administration of effective amounts of hyaluronic acid - Google Patents

Oral administration of effective amounts of hyaluronic acid

Info

Publication number
AT282418T
AT282418T AT97900058T AT97900058T AT282418T AT 282418 T AT282418 T AT 282418T AT 97900058 T AT97900058 T AT 97900058T AT 97900058 T AT97900058 T AT 97900058T AT 282418 T AT282418 T AT 282418T
Authority
AT
Austria
Prior art keywords
oral administration
hyaluronic acid
effective amounts
amounts
effective
Prior art date
Application number
AT97900058T
Other languages
German (de)
Inventor
Eva Anne Turley
Samuel Simon Asculai
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002167044A priority Critical patent/CA2167044C/en
Priority to CA 2193921 priority patent/CA2193921A1/en
Application filed by Jagotec Ag filed Critical Jagotec Ag
Priority to PCT/CA1997/000007 priority patent/WO1997025051A1/en
Publication of AT282418T publication Critical patent/AT282418T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT97900058T 1996-01-11 1997-01-08 Oral administration of effective amounts of hyaluronic acid AT282418T (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002167044A CA2167044C (en) 1996-01-11 1996-01-11 Oral administration of effective amounts of forms of hyaluronic acid
CA 2193921 CA2193921A1 (en) 1996-12-24 1996-12-24 Oral administration of effective amounts of forms of hyaluronic acid according to various standards
PCT/CA1997/000007 WO1997025051A1 (en) 1996-01-11 1997-01-08 Oral administration of effective amounts of forms of hyaluronic acid

Publications (1)

Publication Number Publication Date
AT282418T true AT282418T (en) 2004-12-15

Family

ID=25678296

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97900058T AT282418T (en) 1996-01-11 1997-01-08 Oral administration of effective amounts of hyaluronic acid

Country Status (11)

Country Link
US (1) US6537978B1 (en)
EP (1) EP0873128B1 (en)
JP (1) JP2000502714A (en)
AT (1) AT282418T (en)
AU (1) AU732344B2 (en)
DE (1) DE69731610T2 (en)
ES (1) ES2231854T3 (en)
HU (1) HU9902285A3 (en)
IL (2) IL124977D0 (en)
MX (1) MX9805588A (en)
WO (1) WO1997025051A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
CN1116044C (en) * 1998-06-24 2003-07-30 凌沛学 Antisticking particle and powder containing sodium hyaluronate and their preparation process
CA2361268C (en) 1999-02-01 2014-06-10 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
AU2005227417C1 (en) * 2000-07-31 2008-10-16 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
JP4992162B2 (en) * 2000-11-27 2012-08-08 大正製薬株式会社 Oral solution containing iron ions
AT417617T (en) * 2001-03-15 2009-01-15 Seikagaku Kogyo Co Ltd Means to control the expression of il-12
US7635489B2 (en) 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
US6806259B2 (en) * 2001-12-21 2004-10-19 Soft Gel Technologies, Inc. Hyaluronic Acid in soft gel form
EP1476471A4 (en) * 2002-01-23 2005-03-16 Inst Of Nutraceutical Res Pty Nutraceuticals for the treatment, protection and restoration of connective tissues
DE10246340A1 (en) * 2002-10-04 2004-04-29 Wohlrab, David, Dr. Combination preparation of hyaluronic acid and at least one local anesthetic and its use
US7060691B2 (en) * 2002-10-10 2006-06-13 Giuseppe Petrigni Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases
JP2005213210A (en) * 2004-01-30 2005-08-11 Seikagaku Kogyo Co Ltd Agent for promoting formation of complex of hyaluronan-associated protein with hyaluronan
US7956180B2 (en) * 2004-05-27 2011-06-07 Novozymes A/S Dried and agglomerated hyaluronic acid product
US7405871B2 (en) * 2005-02-08 2008-07-29 Intel Corporation Efficient EUV collector designs
US8598144B1 (en) 2005-11-10 2013-12-03 Reyn Pharma, Llc Method of administering hyaluronan formulation for the amelioration of osteoarthritis
US9492381B1 (en) 2005-11-10 2016-11-15 Reyn Pharma, Llc Method of administering hyaluronan formulation for preventing and ameliorating osteoarthritis
US20080051367A1 (en) * 2006-08-23 2008-02-28 Huan-Ching Hsu Hyaluronan used in improvement of anti-oxidation and proliferation in chondrocytes
WO2008060466A2 (en) * 2006-11-10 2008-05-22 Cytori Therapeutics, Inc. Individualized dosage determination for local administration of therapeutic particles
US8163716B1 (en) 2008-06-30 2012-04-24 Smith James D Method of administering hyaluronan formulation for the amelioration of osteophytes
US8178511B1 (en) 2008-07-02 2012-05-15 Smith James D Method of administering hyaluronan formulation for the amelioration of osteopenia
US8462765B2 (en) * 2008-08-20 2013-06-11 Qualcomm Incorporated Method and apparatus to perform ranging operations for wireless stations
JP5601805B2 (en) * 2009-08-24 2014-10-08 キユーピー株式会社 Oral dry eye improving agent, and food composition and pharmaceutical composition containing the oral dry eye improving agent
WO2012154738A1 (en) 2011-05-09 2012-11-15 The Cleveland Clinic Foundation Composition and method to improve intestinal health
WO2015022670A1 (en) * 2013-08-14 2015-02-19 Stempeutics Research Pvt. Ltd. Management of osteoarthritis using pooled allogeneic mesenchymal stem cells
DE202017107170U1 (en) 2017-11-27 2018-02-16 Proceanis Gmbh Hyaluronan-containing oral composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
WO1994007505A1 (en) 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
US5834444A (en) * 1991-07-03 1998-11-10 Hyal Pharmaceutical Corporation Hyaluronic acid and salts thereof inhibit arterial restenosis
FR2691066B1 (en) * 1992-05-15 1995-06-09 Sanofi Elf Use of exogenous glycosaminoglycans, their analogs as well as their fragments, fractions and derivatives, for the preparation of medicaments for the treatment of thrombopenia.

Also Published As

Publication number Publication date
EP0873128B1 (en) 2004-11-17
AU732344B2 (en) 2001-04-12
ES2231854T3 (en) 2005-05-16
MX9805588A (en) 1998-10-31
IL124977A (en) 2006-10-31
HU9902285A2 (en) 1999-11-29
HU9902285A3 (en) 2001-07-30
EP0873128A1 (en) 1998-10-28
WO1997025051A1 (en) 1997-07-17
AU1187697A (en) 1997-08-01
IL124977D0 (en) 1999-01-26
DE69731610D1 (en) 2004-12-23
DE69731610T2 (en) 2005-12-01
US6537978B1 (en) 2003-03-25
JP2000502714A (en) 2000-03-07

Similar Documents

Publication Publication Date Title
DK0731694T4 (en) Opioid formulations for the treatment of pain
DK0679400T3 (en) Oral dosage forms of azithromycin to avoid drug-food interaction
DE69732049D1 (en) Pharmaceutical preparations, containing salts of hyaluronic acid and local anesthetics
DE69627690D1 (en) Liposomal formulations of mitoxantron
DK0928184T3 (en) Oral anti-caries compositions
DE69910186D1 (en) Pharmaceutical composition of topiramate
DE69432076T2 (en) New pharmaceutical formulations
DE69331409T2 (en) Oral 1alpha hydroxyprevitamin d
DE69739894D1 (en) Process for the preparation of docosahexanoic acid and docosapentanoic acid
DE69618587D1 (en) Chinazoline and pharmaceutical compositions
DE69826683D1 (en) Therapeutic compositions containing amlopidine and atorvastatine
DE69804281D1 (en) Pharmaceutical compositions for the treatment of liver diseases
DE69619832D1 (en) Pain-relating composition of medicinal products
DE69525148T2 (en) Pharmaceutical formulation
DE69736066D1 (en) Pharmaceutical compositions contain s - (-) - n-propargyl-1-aminoindane
DE69428040T2 (en) Oral pharmaceutical form
PT0900782E (en) Ester of 2-cyanacrylic acid
DE69520399T2 (en) Dental restoration structure
DK1027038T3 (en) Taste-masked pharmaceutical compositions
DK0754061T3 (en) New oral pharmaceutical dosage form
FI963421A (en) Oral excipient compositions
BR9504452A (en) Pharmaceutical compound and formulation
BR9504060A (en) Compound and pharmaceutical formulation
BR9500784A (en) Compound and pharmaceutical formulation
PT1043977E (en) Form of oral pharmaceutical dosage of liberation by impulses

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties